EGF and decubitus ulcer: Upton et al. conducted a clinical trial composed of 30 patients suffering from pressure ulcers, diabetic foot ulcers, and venous leg ulcers on which they only observed two cases of adverse events associated with insulin-like growth factor (IGF) and epidermal growth factor (EGF) when 132.5 μg of vitronectin was topically applied.